Listed

Immunovant, Inc.: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 12, 2020 and accepted by EDGAR at Nov 12, 2020, 08:30 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-07-01 to 2020-09-30$12.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-04-01 to 2020-09-30$28.9mus-gaap:ResearchAndDevelopmentExpense
Interest expense3 months2020-07-01 to 2020-09-30$0us-gaap:InterestExpense
Interest expense6 months2020-04-01 to 2020-09-30$0us-gaap:InterestExpense
Income tax3 months2020-07-01 to 2020-09-30$40.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2020-04-01 to 2020-09-30$88.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-07-01 to 2020-09-30−$20.8mus-gaap:NetIncomeLoss
Net income6 months2020-04-01 to 2020-09-30−$47.5mus-gaap:NetIncomeLoss
Operating cash flow6 months2020-04-01 to 2020-09-30−$38.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2020-04-01 to 2020-09-30$86.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-09-30$444.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$450.3mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$453.9mus-gaap:Assets
Current liabilitiesAt period end2020-09-30$12.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-30$15.5mus-gaap:Liabilities
Shareholders' equityAt period end2020-09-30$438.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001764013-20-000063. Last ingested by Listed: Nov 13, 2026, 16:26 ET. Listed shows no prices and gives no investment advice.